These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
581 related articles for article (PubMed ID: 27143245)
1. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245 [TBL] [Abstract][Full Text] [Related]
2. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095 [TBL] [Abstract][Full Text] [Related]
3. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019 [TBL] [Abstract][Full Text] [Related]
4. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. Khalid F; Healy BC; Dupuy SL; Chu R; Chitnis T; Bakshi R; Houtchens M J Neurol Sci; 2018 Sep; 392():94-99. PubMed ID: 30031994 [TBL] [Abstract][Full Text] [Related]
5. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis. AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574 [TBL] [Abstract][Full Text] [Related]
6. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094 [TBL] [Abstract][Full Text] [Related]
7. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis. Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108 [TBL] [Abstract][Full Text] [Related]
8. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979 [TBL] [Abstract][Full Text] [Related]
9. Significant clinical worsening after natalizumab withdrawal: Predictive factors. Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320 [TBL] [Abstract][Full Text] [Related]
10. Two-year regional grey and white matter volume changes with natalizumab and fingolimod. Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638 [TBL] [Abstract][Full Text] [Related]
11. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Eshaghi A; Prados F; Brownlee WJ; Altmann DR; Tur C; Cardoso MJ; De Angelis F; van de Pavert SH; Cawley N; De Stefano N; Stromillo ML; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Vrenken H; Leurs CE; Killestein J; Pirpamer L; Enzinger C; Ourselin S; Wheeler-Kingshott CAMG; Chard D; Thompson AJ; Alexander DC; Barkhof F; Ciccarelli O; Ann Neurol; 2018 Feb; 83(2):210-222. PubMed ID: 29331092 [TBL] [Abstract][Full Text] [Related]
12. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361 [TBL] [Abstract][Full Text] [Related]
13. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial. Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809 [TBL] [Abstract][Full Text] [Related]
14. Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. Deppe M; Marinell J; Krämer J; Duning T; Ruck T; Simon OJ; Zipp F; Wiendl H; Meuth SG Neuroimage Clin; 2014; 6():475-87. PubMed ID: 25610761 [TBL] [Abstract][Full Text] [Related]
15. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies. Pawate S; Wang L; Song Y; Sriram S J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826 [TBL] [Abstract][Full Text] [Related]
16. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349 [TBL] [Abstract][Full Text] [Related]
18. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings. Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963 [TBL] [Abstract][Full Text] [Related]